

# Charitable Program Overview



**Clorinda Walley**  
President & CEO



# About Good Days

- Founded in 2003 by a person who has a chronic disease and understood the financial burden that individuals in this country are facing when diagnosed with a life altering disease
- We are an organization that not only understands, but has a true commitment to helping people remove barriers to care
- Through financial assistance for out-of-pocket copay, travel, premium and diagnostic costs, we are giving those we help more Good Days
- We connect people with advocacy organizations throughout the country to fulfill the needs we cannot meet including psychosocial support and everyday life needs



# Vision, Mission, and About Us

**Our vision is a world in which no one has to choose between access to care and everyday necessities so that people can have more good days**



**Good Days is a national non-profit charitable organization that lifts the burdens of chronic illness through assistance, advocacy, and awareness**



**Good Days** is a national non-profit advocacy organization that provides patient assistance and financial resources for life-saving and life-extending treatments to people in need



**Chronic Disease Day** is an awareness campaign led by the national non-profit Good Days, that uses peoples' stories and voices to advocate to lower the number of preventable illness, advance access to care for unpreventable conditions, and build healthier communities

# OIG Solution

- 2005: OIG issues a Special Advisory Bulletin entitled: “Patient Assistance Programs for Medicare Part D Enrollees”

- In Summary:

*The OIG would prefer for manufacturers to support financially needy Part D enrollees by making charitable contributions to independent charities. Assistance provided by a charity that is unaffiliated with a pharmaceutical manufacturer will not normally implicate the anti-kickback statute. Moreover, the support provided by these charities to Part D enrollees will count toward each recipient’s out of pocket requirement for reaching catastrophic coverage, referred to as “true out of pocket expense” or “TrOOP.”*



# OIG Modifications

## 2014 - OIG issues Special Advisory Bulletin: “Independent Charities Patient Assistance Programs”

*In Summary: The OIG has seen a general tendency away from the broad disease funds toward much narrower funds. The OIG sees these restrictions as harmful to patients, taxpayers and Federal programs. If assistance is available only for the highest cost drugs, patients may be steered to those drugs rather than to equally effective, lower cost alternatives. A broader range of equally effective treatments offer greater freedom of choice. The OIG considers these to be key safeguards to ensuring a charities independence from its donors.*

- All programs will include the coverage of generics
- Programs should not be narrowly defined
- **Single drug categories are not permissible.** A category with only one product available must offer additional paid services, i.e., premium assistance, travel assistance, etc. The program will be a disease program, not a co-pay program.
- **Metastatic disease is approved.** If a patient’s disease has become controlled and is no longer metastatic, the patient’s continued treatment must be covered as part of this fund.



# Ophthalmology Program Background

- June 2006 - FDA Approved first treatment for AMD
- Multiple treatments have been approved since then
  - Majority of people affected are on Medicare and cannot afford the out-of-pocket expense
- 2006 - Good Days opened AMD Copay Assistance Program
- 2010 - Good Days opened RVO Copay Assistance Program
- 2014 - Good Days combined all Macular Diagnosis - MAC\* Program
- 2014 - Good Days combined all Retinal Diagnosis - RET\* Program
- Early 2019 - Good Days opened CNIU Copay Assistance Program


\*Age-Related Macular Degeneration, Cystoid Macular Edema, Diabetic Macular Edema, Macular Edema, Myopic Choroidal Neovascularization, Vitreomacular Adhesion

\*Central Retinal Vein Occlusion, Diabetic Retinopathy, Retinal Edema, Retinal Neovascularization, Retinal Vein Occlusion, Venouse Tributary Occlusion

Good Days covers all FDA-approved treatments for these diagnoses




# Financial Assistance Provided



# MAC Program

■ Total Enrollments      ■ Funded Enrollments






# RET Program

■ Total Enrollments

■ Funded Enrollments



# Good Days Assistance Summary

- Good Days has approved over 2.48 million\* grants
- We have provided over \$2.66 billion\* dollars in assistance
- Average payment for following:

	<u>Diagnosis</u>	<u>Over-All</u>	<u>2024**</u>
–	MAC	\$1,093.72	\$1,119.36
–	RET	\$879.97	\$850.53

\* As of March 3, 2025

\*\* Still paying 2024 claims



# Ways You Can Help

The need is ever growing...

We are all in this together...

To continue to help the people we serve,  
please consider donating:

<https://www.mygooddays.org>



# Thank you!

